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Abstract
Recent advancements in cancer research has led to the synthesis of a new drug known as
docetaxel. Meant to replace paclitaxel, its more natural counterpart whose ingredients are difficult
to obtain, the drug is known to effectively treat a wide array of cancers, including breast cancer,
ovarian cancer, and prostate cancer. The establishment of a synthetic alternative to paclitaxel has
increased its bioavailability, thereby lowering the cost needed to utilize the drug. Still, the limiting
factor in minimizing costs is the method in which the drug is processed. Current methods in drug
processing have their limitations, which include the introduction of impurities and a low effective
yield due to poor powder geometry. Thus, the goal of this study looks to explore a new way to
process the drug in a more efficient manner.
In this study, a new method for processing docetaxel is explored on in great detail. A more
direct method of using electrospray deposition is utilized for the creation of monodisperse
nanoparticles, with the main intention of increasing the efficiency at which the drug is processed
and prepared for drug delivery to the patient by means of injection. A key feature in electrospray
deposition is its ability to produce droplets that are sized homogenously. These droplets eventually
evaporate at homogenous rates. These two concepts have been exploited to consistently produce
nanoparticles of the cancer drug, which is made possible by the fact that the minimal variation in
droplet sizes has easily translated to minimal variation in dry particle sizes. Compared to other
methods of drug processing, one other benefit that electrospray deposition conveys is that through
evaporation, virtually all impurities and unwanted foreign material are eliminated.
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Moreover, a binary solvent system is investigated in more detail in this study, so as to
determine its effects on both the evaporation of the solvent and the diffusion of the drug into
nanoparticles. From there, material and geometric properties of the electrospray nozzle were
explored upon in great detail, with the main goal of being able to produce a cone jet that
consistently dissociates into monodisperse droplets. At the same time, controllable properties of
the electrospray atomizer were investigated and continuously modified. Modifications in both the
components of the solution and the operating temperature were also considered to enhance both
the electrospray deposition process and the geometry of the particles. Scanning electron
microscopy (SEM) characterization is continuously utilized to determine suitability of results
obtained in experiments.
Ultimately, the goal of this study is to determine the ideal conditions (solvent ratios, flow
rate, operating temperature, electrospray atomizer nozzle configurations, etc.) in which spherical
docetaxel particles sized at 100-200 nm can be produced.
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Chapter One: Biochemical Background
1.1.

Introduction
Recent advancements in pharmaceutical research has led to the creation of a wide array of

drugs capable of treating different cancers. While these drugs do destroy tumors, the effectiveness
at which they do so can be largely hampered on the nanoscale level by which the drugs have been
processed. Inconsistencies in particle geometry can lead to issues such as improper drug intake
and reduced effectiveness of treatment. This study attempts to circumvent such issues by using
electrospray deposition as the conduit for which particles with more consistent geometry can be
produced.
This contribution primarily focuses on docetaxel as the model drug, with occasional
experiments being performed on a similar drug known as paclitaxel. The two drugs behave
similarly when it comes to treating diseases such as breast cancer and prostate cancer.
Bioavailability
Paclitaxel was originally the first-choice drug for treating cancers. It is primarily obtained
from the bark of the Pacific Yew tree in the form of an extract. However, due to the scarcity of the
source tree, docetaxel has been artificially synthesized to serve as a less expensive substitute, and
has therefore been more easily marketed than its natural counterpart. (1)
Additionally, studies were conducted to determine if there were differences in the efficacies
of the two drugs. Researchers were able to prove that docetaxel exhibits more effectiveness in
treating the same cancers. (2-4)
1

1.2.

Background
Mechanism Overview
Like most cancer drugs, docetaxel treats breast and prostate cancer through multiple

different fronts. These can include inhibiting tumor growth, preventing the division of the infected
cell, preventing transmittance to other cells, and even outright destroying the infected cell.
However, before combatting the tumor, the drug is to naturally be first taken to the cancer
site. Docetaxel is primarily distributed as a drug dissolved in an alcoholic solution, and is to be
injected into the patient by means of a needle. From there, cells in the body transport the drug
eventually to the cancer site by means of natural circulation. (5)
Morse, Gray, et al, determined that the main mechanism at which docetaxel functions is
through a process known as mitotic catastrophe. Here, docetaxel disrupts mitosis by first disrupting
the division of the chromosomes. From there, cell division does occur, but the new cells contain
poorly-structured nuclei and significantly-shrunk cytoplasm, thereby rendering them unable to
reproduce and spread the cancer elsewhere. Ultimately, the unhealthy cells, which are severely
damaged at this point, eventually die out. (6)
Surfactants
To facilitate such a process, the additive D-α-tocopheryl polyethylene glycol succinate,
better known as vitamin E TPGS, is introduced to the solution of the drug as a surfactant. The
surfactant has a wide array of purposes, ranging from increasing the solubility of the docetaxel
itself to increase the efficiency of the drug delivery process.
2

In the chemical context, docetaxel on its own has an extremely low threshold for solubility
due to its molecular structure. This is largely due to polarity; docetaxel molecules exhibit minimal
dipole moment, as presented in the bond-line structure shown in Figure 1 below. (7)

Figure 1: Molecular structure of docetaxel.

As shown in the structure, docetaxel contains two aromatic rings, as well as a nonelongated core. These two substituents, as well as a central nine-membered bridged ring, minimize
the overall polarity of the drug, thus rendering it insoluble to the organic solvents used in this
study. Consequently, the introduction of vitamin E TPGS increases the solubility of the drug in
increasing polarity. This is achieved through a unique structure, shown below in Figure 2. (8)

Figure 2: Structure of vitamin E TPGS, which contains both polar and nonpolar components.
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Fundamentally, vitamin E TPGS contains both polar and nonpolar components. Solubility
is increased in that the nonpolar core affixes onto the drug molecules, while the polar tails are used
to increase attraction towards the solvent.
The introduction of vitamin E TPGS also increases the efficacy at which the drug treats the
cancer cells. Zhang, Tan, et al, was able to demonstrate this by conducting experiments that
compared the degradation rates of TPGS-emulsified docetaxel to that of docetaxel without
modifications. These degradation rates, in turn, reflect the strength of the drug upon reaching the
tumor. A higher concentration over a longer time period implies that the drug did not severely
degrade during the transport process. The longer durability of the TPGS-emulsified docetaxel in
Figure 3 shows that vitamin E TPGS is an excellent conduit for ensuring that the docetaxel is
effective in its purpose. (8)

Figure 3: Degradation of docetaxel (commercially marketed as Taxotere) as compared to docetaxel
emulsified with TPGS (indicated by NP).
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Stipulations
In general, the effectiveness of the treatment is largely limited to the geometry of the
powders formed during processing. In order for the drug to be able to be able to bypass the immune
system and be transported to the site of the tumor by means of cellular processes, its powders must
be of a spherical shape ranging approximately 100-200 nm.
Such stipulations are put in place in that there are adverse effects when deviations from the
recommended geometry are present. For instance, particles that are too large (i.e. a diameter greater
than 200 nm) are more likely to be rejected by the immune system, which can mistake the drug for
foreign matter. (9) On the other hand, in spite of particles smaller than 100 nm being able to easily
bypass such defenses, a smaller size significantly inhibits the efficiency at which the drug is
encapsulated. (10-11) Thus, particles in the optimal size range of 100-200 nm will be able to not
only avoid rejection, but also be able to successfully prevent the growth of the tumor.
Lastly, a perfectly spherical particle geometry is necessary for the surfactant to form
micelles around the nanoparticles, a necessary step in making possible the delivery of the drug to
the cancer site without unintentionally damaging innocent cells.
Thus, this contribution largely focuses on using a binary solvent system and electrospray
deposition as a technique to achieve such a desired particle morphology.

5

1.3.

Current Drug Processing Techniques
Currently, there are different methods of preparing the drug for delivery in achieving such

a particle morphology, but each one has its set of drawbacks, ranging from low yield to high
process complexity.
Wet Milling
One possible method for processing the drug is through wet milling. Originally, wet milling
was considered as the ideal method for processing docetaxel in that dissolution through a solvent
was not needed. Instead, the drug is placed in bulk inside a milling chamber along with milling
pearls. Both the pearls and the bulk drug are spun at high revolution rates. Through collisions with
the pearls, the walls of the chamber, and other drug particles, the drug is eventually reduced into a
set of superfine particles.
While the wet milling might seem attractive due to its ability to generate nanoscale particles
of poorly soluble drugs with consistent geometry, the main risk with such a processing method is
that it can lead to contamination from the pearls. During the milling process, the pearls may be
damaged due to the violent collisions, and pieces of the oftentimes ceramic material may mix in
with the drug and do so undetected. Additionally, the yield generated from such a process is
relatively poor. (11-12)
Precipitation
A simpler way of processing docetaxel is through a process known as precipitation. Here,
the drug is simply dissolved in a solvent-antisolvent pair (i.e. two complementary, but immiscible
6

solvents). Miscibility between the two solvents and the solubility of the drug in the solvent pair is
forced through sonication or constant stirring. Through nucleation, nanoparticles quickly form at
the conclusion of the process.
Here, the main limiting factor is that there is little to no control when it comes to achieving
the desired particle geometry. Consequently, the effective yield attained in such a process is
severely minimized, and filtering out the correct particles is a laborious process on its own. (13)
Coaxial Electrospray Deposition
Other research groups such as Cao, Luo, et al, did in fact attempt to use electrospray
deposition as a technique for processing bulk paclitaxel into fine powders (which can be translated
into processing docetaxel). (14) However, they did so in an indirect manner, using a system
consisting of coaxial nozzles. Each of the three nozzles deposited one of the following
components: a core (the drug), a shell, and a corona. Figure 4 demonstrates the process in which
electrospray deposition was used as a tool for generating nanoparticles of paclitaxel.

Figure 4: Schematic diagram of the coaxial electrospray method to produce monodisperse nanoparticles,
followed by the removal of the corona.
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Here, electrospray deposition was used to generate tri-layered particles. A suspension
system was then used to eliminate the corona. The drug and its accompanying polymeric shell was
then filtered from the colloid. (14)
While this method does produce nanoparticles with consistent geometry and with no effect
on the capabilities of the drug, its main drawback is the low yield that is achieved due to the
stipulation of separating the corona from the core and the shell. Thus, in this study, a more direct
method of using the electrospray for the purpose of the drug delivery of docetaxel is investigated.
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Chapter Two: Electrospray Fundamentals
2.1.

Motivation
The main purpose of this study is to be able to determine the optimal conditions for which

the electrospray can be used to process a cancer drug known as docetaxel. The idea is to dissolve
bulk amounts of docetaxel in a binary solvent system, and from there use the capabilities of
electrospray atomization to produce monodisperse droplets. These droplets then evaporate in a
two-stage manner: first quickly, followed by a much slower evaporation to gain control over the
particle re-formation process of the solid docetaxel drugs.
In doing so, the aim is to demonstrate that electrospray deposition is an excellent conduit
for increasing the efficiency of the drug delivery process, as well as to maximize the amount of
usable yield by being able to homogenize the geometry of the drug particles in terms of both size
and shape. Particle geometry is important with regards to increasing the likeliness of the body’s
acceptance of the drug and its transportation to the site of the tumor.

2.2.

Overview of Electrospray Deposition
Jet Formation
Fundamentally, electrospray deposition works by having an extremely narrow pipe known

as a capillary (order of microns or millimeters) that is open on one end, wherein the exposed end
faces a deposition plate in an orthogonal manner. This opening is spaced away from the deposition
9

area by merely a few centimeters. The capillary, which either has a metallic segment connected to
a non-metallic material (e.g. silica) or is entirely metallic, is connected to a high voltage source.
During operation, the liquid solution flows through the pipe from a syringe by means of a
pump or pressurized gas. The high-voltage source, which is connected to the metallic segment of
the capillary, provides electric charge to the solution itself by introducing a potential difference in
the order of kilovolts (kV). As a result, the solution is drawn towards the center of what is known
as a cone jet, wherein a narrow column of the fluid is formed. (15)
Eventually, this column dissociates into a series of droplets, which evaporate quickly due
to the extremely small surface area. If the solution contains solutes that are normally solid at the
established operating temperature, their particles fall onto a grounded collection plate, which can
have a small collection chip in the form of aluminum foil or a piece from a silicon wafer. Figure 5
illustrates the process, starting from the pumping of the liquid all the way to the collection of dry
particles on a grounded surface. (15)
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Figure 5: Simple schematic of electrospray deposition.

Jet Stability
With regards to operating an electrospray atomizer, multiple facets could be adjusted, each
one yielding different results. Typically, parameters such as inner diameter nozzle, applied voltage,
flow rate, and, in some cases, the operating temperature are adjusted to accommodate the user’s
desired deposition behavior.
Regardless of other parameters, it is oftentimes the applied voltage that dictates what mode
of deposition is generated. Typically, electrospray deposition involves three modes: first, the
dripping mode, wherein extremely large droplets are created without the involvement of a cone
jet. The stable cone jet mode entails one cone-shaped jet being formed and breaking up into a
successive series of droplets that are both smaller and more consistently-sized. Lastly, the multijet mode entails behavior similar to that of fire sprinklers, wherein multiple jets are formed, each
one successively disintegrating into much smaller droplets. These three behaviors are achieved
through different levels of applied voltage, which is tabulated in Table 1. (15)
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Applied Voltage Range (kV)

Electrospray Behavior

0–2

Dripping Mode

2–3

Stable Cone-Jet Mode

3 – 15

Multi-Jet Mode

Table 1: Electrospray behaviors at different levels of applied voltage.

While applied voltage dictates behavior, finer control of droplet and dry particle sizes could
be achieved by varying both the flow rate and the inner diameter of the nozzle. In general, droplet
size is directly proportional to both flow rate and nozzle inner diameter. Past studies have proposed
different scaling laws. Zarrabi and Vossoughi, for instance, proposed that
1

𝑑𝑝 =

3
𝜌 𝑤
(𝜌 𝑤+𝜌𝑠 (1−𝑤) 𝑑 3 )
𝑠
𝑝

where dp is dry particle size, d is the droplet size, w is the weight fraction of the solid solute in the
liquid solvent, ρs is the density of the solvent, and ρp is the density of the solid solute. (16)
For binary solvent systems, the density of the solvent can be defined as
𝜌𝑠 = 𝜌1 𝑉1 + 𝜌2 𝑉2
where ρ1 and ρ2 are the densities of the two solvents, and V1 and V2 are their respective volume
percentages
Additionally, for droplet size, Deng, Gomez, et al, proposed that
1

𝑑=

𝑄𝜖𝜖 3
𝐺(𝜖) ( 𝛫 0 )
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where G(ϵ) is a function relatively close to unity, Q is the flow rate, ϵ and ϵ0 are relative
permittivities of the fluid and of free space, respectively, and Κ is the fluid conductivity. (15)
Wetting
During experimentation, it has been discovered that one way that a stable jet could be
disrupted is through a phenomenon known as wetting. Here, the surface tension of the solution
dominates over the electromotive force necessary to break the jet of the solution up into
monodisperse droplets. Consequently, the jet of the solution sticks to the outer walls of the nozzle,
where more energy is required to produce the droplets. Due to the higher force requirement, larger
droplets are sometimes produced. In terms of morphology, this translates to drug particles that
have inconsistent size and shape. Figure 6 demonstrates how such a phenomenon arises.

(a)

(b)

Figure 6: Electrospray jets in (a) an instance of wetting, and (b) stable mode.

In order to address such an issue, the primary strategy is to draw flow away from the sides
of the nozzle and towards the center of the inner diameter. This was achieved using a combination
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of two methods: applying a hydrophobic coating on the nozzle, or inserting a conductive needle
that would draw the jet towards its tip, which is concentric with the inner diameter of the nozzle.

2.3.

Chemical Properties of Solvents
Miscibility
In molecular context, chemical concepts suggest that, in a binary solvent system, two

solvents are miscible or immiscible to each other due to the geometry of the molecules of the two
solvents. Common knowledge dictates that two nonpolar solvents are miscible and that two polar
solvents are also miscible, but a polar and a nonpolar solvent are immiscible with each other.
However, in certain cases, the miscibility of two solvents may not be as clear-cut as being
entirely soluble or insoluble, as some of the solvents used in this study have both polar and
nonpolar components. A situation could arise wherein miscibility could only occur at certain ratios
of the two solvents. Immiscibility occurs at a so-called miscibility gap, wherein at lower
temperatures, it is highly likely that the two solvents coexist as two distinct phases in the same
container. (17-18) Oftentimes, the miscibility gap occurs at low ratios of solutions, where the
composition of one solvent does not clearly dominate over the other, as demonstrated in Figure 7,
where mixtures of nitrobenzene in hexane has been used as an example. (18)
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Figure 7: Phase diagram demonstrating miscibility gap present in mixtures of hexane (primary solvent)
and nitrobenzene (secondary solvent) across different temperatures and compositions, at 1 atm presssure.
The miscibility gap area is indicated by P = 2.

In order to circumvent such an issue, the binary solvent systems utilized in this study are
mixed in ratios of at least nine-to-one, so as to ensure miscibility, regardless of molecular structure.
In fact, such a ratio is also favorable with regards to the thermodynamic properties of the solution,
which is to be discussed later.
Moreover, beyond composition, other parameters such as vessel pressure and temperature
could be modified to influence the solubility of the two solvents with each other, but due to
experiments being conducted largely at room temperature, such parameters have easily been
overlooked in favor of working with the compositions of the solvent instead.
Thus, in this study, different pairings of organic solvents were used: water in ethanol;
dimethyl sulfoxide (DMSO) in ethanol; and acetone in ethanol.

15

Solubility of Docetaxel in Solvents
For the most part, docetaxel is almost entirely insoluble in water. However, at low weight
percentages, docetaxel is soluble in a wide variety of organic solvents, including dimethyl
sulfoxide and ethanol. According to LC Laboratories, the company from which the docetaxel used
in this study was obtained, the saturation point for docetaxel in DMSO occurs at 200 mg/mL, while
the saturation point for docetaxel in ethanol occurs at 100 mg/mL. (19)
Compatibility with Electrospray
The feasibility at which the solvents could be electrosprayed could be determined in terms
of fluid conductivity. Multiple methods have been utilized for determining the compatibility with
the electrospray, wherein smaller droplets, and therefore smaller powders, are produced when the
drug is dissolved in a more conductive organic solvent.
One such method is through the determination of relative polarity of the organic solvents,
which is influenced by factors such as ability to form hydrogen bonds, electronegativity of
constituent atoms, and the net dipole moment of the molecules. (20) While also useful in
determining other properties such as boiling and freezing points, the relative polarity is also a
useful metric in determining the effectiveness of the solvents in the electrospray deposition
process. Table 2 below lists the polarities of the various organic solvents utilized in this study,
with water as the reference solvent. (21)
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Organic Solvent

Relative Polarity

Acetone

0.355

DMSO

0.750

Ethanol

0.654

Water

1.000

Table 2: Relative polarities of selected organic solvents.
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Chapter Three: Mass and Thermal Transport
3.1.

Overview
In general, the entire electrospray deposition process can be divided into three different

processes: the formation of the jet within the neighborhood of the nozzle, followed by the
dissolution into monodisperse droplets, and concluded by the evaporation of the droplets. The last
step of this process occurs simultaneously with the diffusion of the solute drug into individual
particles, which is to be collected for future use. Each of these steps can be accounted for in terms
of the rates at which they happen and the energy required to make them happen.

3.2.

Jet Dynamics
Solution Properties
For the solvents used throughout the study, there are but a few important parameters that

dictate the overall behavior of electrospray deposition. These properties are all dictated by polarity,
as described earlier in Section 2.3.3. Among these properties include density ρ, surface tension γ,
dynamic viscosity µ, electrical conductivity k, and dielectric constant ϵ. In the deposition process,
these four properties play a huge role in governing the vital facets of the overall formation of the
drug particles, including droplet size, solvent evaporation, and nucleation of the drug. Table 3
below lists the said properties for the four primary solvents discussed in this study at room
temperature. (22)
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Organic

Density

Surface Tension

Dynamic Viscosity

Electrical

Dielectric

Solvent

(ρ, g/mL)

(γ × 103, N/m)

(µ × 103, N∙s/m2)

Conductivity

Constant

(k × 109, S/cm)

(ϵ)

Acetone

0.790

23.30

0.33

5.0

20.6

DMSO

1.101

43.70

2.00

2.0

46.6

Ethanol

0.789

22.40

1.08

1.4

22.3

Water

0.998

72.75

0.89

5.0 × 108

79.7

Table 3: Relevant Properties for organic solvents. handbook of organic solvents

Due to the presence of charge in the liquid solution, which is provided beforehand by a
certain range of voltages from a voltage source, the outflow of solution exiting the nozzle will
naturally converge towards a certain point, which is the tip of the cone jet. The convergence
towards this central point leads to an accumulation of charge, which translates to an electromotive
force. Coupled with the inertia presented by the mass flow rate, these two forces overcome the
surface tension that keeps the jet bound together. Such a phenomenon is accounted for by the
Weber number, which is defined by
𝜌𝑣 2 𝑙
𝑊𝑒 =
𝛾
where ρ is density, v is velocity (assuming constant cross-section area of flow), and l is the
characteristic length along the jet. (23)
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The Weber number, in other words, is simply the ratio between the inertia of the fluid and
its surface tension. At a certain vertical length of the cone jet, We = 1. Here, the jet dissociates into
a series of monodisperse droplets, as shown in Figure 8. (15)

Figure 8: Breakup of jet into droplets.

3.3.

Solvent Evaporation
The next step that follows the breakup of the cone jet and droplet formation is the

evaporation of the droplet, which occurs simultaneously with the nucleation and growth of the
solid drug into the sought-after particles.
Evaporation Rate for Single Solvent System
For a single solvent system, the time profile at which the liquid droplet evaporates in a
linear manner. The overall time profile at which a droplet evaporates is dependent on both the
properties of the solution and the diameter of the droplet, and is defined by the d2 law:
20

𝑑(𝑡) = 𝑑02 − 𝜅𝑡
where d0 is the initial droplet diameter and κ is an evaporation rate that is dependent on the single
solvent and t is the time and d(t) is the droplet diameter at time t. As described earlier, the initial
droplet size itself is highly dependent on both chemical and electronic properties of the individual
solvent. (24)
The evaporation rate κ is highly dependent on the surface tension of the solvent, as well as
the density and temperature, which is assumed to be constant throughout the process. Vehring, et
al, defines this constant as

𝜅=

8𝐷𝜌𝑔
1 − 𝑌∞
ln (
)
𝜌𝑙
1 − 𝑌𝑠 (𝑇𝑒 )

where D is the diffusion coefficient of the solvent, Y∞ is the concentration of the solvent vapor at
a very large distance away from the droplet (assumed to approach zero), Ys(Te) is the concentration
of the solvent vapor at the surface of the droplet at some steady-state temperature Te, ρg is the
density of gas (assumed to be air in this case), and ρl is the density of the solvent. (25)
From there, the rate at which the droplet shrinks in terms of diameter can also be
approximated by algebraically rearranging the equation presented above when d(t) = 0, which
yields

𝑡𝑒𝑣𝑎𝑝 =
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𝑑02
𝜅

Evaporation Rate for Binary Solvent System
For a binary solvent system, the rates at which the solvent evaporates occurs in two stages:
a fast evaporation stage, in which the solvent with the smaller surface tension evaporates first, then
followed by a slow evaporation stage, in which the remaining solvent evaporates. Due to the
intermolecular forces present between the two solvents, the total time at which the entire solvent
system evaporates cannot be the sum of the evaporation times of the individual solvents as droplets
that are electrosprayed separately. Instead, factors such as miscibility and individual
concentrations of the constituents are taken into account when calculating evaporation time.
Thus, for ease of calculation, the ratios between the two solvents are set such that an ideal
solution is approximated. In other words, a large amount of one solvent is coupled with a small
amount of the other solvent. In addition, the entire process is assumed to be of constant
temperature. Mathematically, one can use mole fractions to approximate the radius of the overall
droplet as a function of time, which Widmann and Davis defines as
𝑑(𝑑𝑝2 )
𝑑02 𝑑𝑉𝑚 2𝑉𝑚
=
−
∑ 𝐷𝑖 𝑥𝑖 𝛾𝑖 𝑃𝑖0
𝑑𝑡
6𝑉𝑚 𝑑𝑡
𝑅𝑇
𝑖

where dp is the diameter of the droplet at some time t, d0 is the initial droplet diameter, Di is the
diffusion coefficient for the solvent, xi is the mole fraction of the solvent, γi is the activity
coefficient of the solvent, and Pi0 is the vapor pressure for the solvent at room temperature, and Vm
is the average molar volume of the components of the droplet, which is defined by
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𝑉𝑚 = ∑ 𝑥𝑖 𝑉𝑖
𝑖

where Vi is the molar volume of the solvent. (26)
Here, a linear relation between the square of the droplet and time is still observed. However,
adjustments have been made to account for mole fraction and the activity coefficients of the
individual constituents towards the solvent.
3.4.

Particle Diffusion
Overview of Diffusion
While the solvent evaporates mid-drop, the solute (in this case, the drug) nucleates and

then grows into a particle. The size of this particle increases over time and is strongly dependent
on the concentration of the drug that is dissolved in the solvent system. The manner in which the
particle diffuses, however, is completely independent of which solvent is present. Fortunately, in
the case of the binary solvent system, the presence of a slow evaporation system due to a solvent
with higher surface tension can prolong the diffusion stage.
Mathematical Interpretation of Diffusion
Regardless of the solvent system, the time profile that the drug undergoes can be first
modelled using the d2 law. For simplicity, the full time it takes for a particle to form after being
dissolved in the solution takes on a similar behavior as the evaporation time. Thus, the time it takes
for the cancer drug to diffuse into an individual particle is loosely defined by
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𝑡𝑑𝑖𝑓𝑓

𝑑𝑝2
=
𝐷𝑠𝑦𝑠

where d is the particle diameter and Dsys is the diffusion coefficient of the system. Here, the particle
diameter is dependent on properties of both the solute and the solvent system. (24)
Many different models have been used to approximate d, but it has been agreed upon that
the particle diameter is strongly dependent on the concentration of the drug dissolved in the
solvent. For example, Hartman, Brunner, et al, defines the particle diameter as

𝑑𝑝 =

1/6
1 𝜌𝜖𝑄 3
3
𝜙 (
)

𝛾𝐾

where ϕ is the concentration of the solute; and ρ, ϵ, Q, γ, and K are the density, dielectric constant,
flow rate, surface tension, and electric conductivity, respectively, for the solvent. Fundamentally,
the equation presented above shows that the particle diameter is largely a function of the cube root
of the concentration and the square root of the flow rate, with the other properties of the solution
exerting much smaller influence. (27)

3.5.

Competition between Evaporation and Diffusion
Ultimately, the final geometry of the particle is dependent on whether the evaporation

process dominates or the diffusion process dominates. This competition is quantified by means of
the Peclet number, which is defined as
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𝑃𝑒 =

𝑡𝑑𝑖𝑓𝑓
𝐾
=
𝑡𝑒𝑣𝑎𝑝 𝐷𝑠𝑦𝑠

Simply put, the Peclet number is the ratio between the diffusion time and the evaporation time,
which is also equivalent to the ratio between the evaporation and diffusion coefficients. (24-25)
If Pe > 1, the particle diffusion dominates the process. Here, unless terminated by landing
at the collection area, the particle will continue to diffuse until its maximum particle diameter,
which can occur even long after the solvent has fully evaporated. What results is the formation of
particles that convey large voids within them.
On the other hand, if Pe = 1, neither the solvent evaporation nor diffusion dominates. At
this condition, a morphology in which disk-shaped or hollow particles are expected to be observed
in that the extent at which the particles have diffused is enough for cavities to form, while the
overall quasi-spherical geometries observed remain intact.
Therefore, the optimal condition in the case of drug processing occurs when Pe << 1. Here,
diffusion terminates well before the evaporation process concludes, thus leading the way for the
formation of ideal aggregates. In this condition, spherical particles do form, and cavities are
completely absent amongst the particles.
Studies performed by Vehring, Foss, et al, have verified such hypotheses. Figure 9 below
shows a sampling of the morphologies of trileucine, a type of protein. (25)
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(a)

(b)

(c)

Figure 9: Morphologies of trileucine at (a) Pe << 1, (b) Pe = 1, and (c) Pe > 1.
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Chapter Four: Experimental Methods
4.1.

Model Drug
Docetaxel (DTX), a drug that is primarily used in the treatment of cancer, is the main drug

to be considered in this study. In some cases, the experiments were done in parallel with a similar
drug known as paclitaxel (PTX). As shown in Figure 10, besides a few differences in functional
groups – i.e. a acetyl group and a phenyl group for paclitaxel, which are replaced by a proton (in
the form of a hydrogen atom) and a tert-butoxide group, respectively, for docetaxel – the two drugs
convey similar structures and thus exhibit similar behavior with regards to how the disease is
treated. (28) However, more thorough studies shows that out of the two, docetaxel is more effective
in the treatment of various cancers. (2-4)

Figure 10: Differences in molecular structure of paclitaxel and docetaxel.
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In this study, both docetaxel and paclitaxel were obtained from LC Laboratories at >99%
purity. Based on the manufacturer, Table 4 below shows relevant properties for the two drugs used
in this study. (19, 29)
Drug

Docetaxel

Paclitaxel

Molecular Formula

C43H53NO14

C47H51NO14

Molecular Weight

807.88

853.91

Solubility in:

DMSO

200

200

(mg/mL)

Ethanol

100

40

Water

<1

<1

Table 4: Relevant properties of paclitaxel and docetaxel.

Due to the better efficacy, as well as due to a higher solubility in ethanol, docetaxel became
the more preferred drug over paclitaxel when it came to performing experiments on the production
of particles.

4.2.

Properties of Atomizer
Nozzle Geometry
In this project, two different aspects of the nozzle were explored upon: the geometry of the

nozzle itself and if any accompanying devices were used to aid the nozzle in manipulating the
shape of the flow.
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As a reference point, electrospray deposition was first done using nozzles with flat surfaces,
as demonstrated in Figure 11a. In this study, standard 27 gauge needles and 30 gauge needles were
used as the baseline nozzles. During such a regime, it was discovered that the surface tension of
the solution caused the liquid to be attracted to flat tip of the nozzle, which eventually led to the
fluid rising up to the outer column of the nozzle tubing. What eventually resulted was an
enlargement of the cone jet. In other words, a nozzle with a flat profile led to inconsistent jet
formation.
In order to circumvent such an issue, one solution that was looked into was the usage of
tapered needles, as illustrated in Figure 11b. In such a nozzle configuration, it is hypothesized that
the absence of a flat surface forced a cone jet to be formed downwards.
Similarly, a second solution was proposed. As shown in Figures 11c and 11d, a tungsten
wire with a diametric thickness of 80 µm was electro-etched in a similar way as the tapering of
certain nozzles, thereby producing a pointed end. With the pointed end facing outward, the tip was
positioned in such a way that the tip was concentric with the opening of the nozzle itself. In doing
so, it has been hypothesized that the tungsten wire will direct the solution towards the center of the
nozzle, thereby producing a cone jet with the aid of the tungsten needle.
The electro-etching was achieved by using the tungsten wire as the anode, while a small
bar made of carbon was used as the cathode. The carbon bar was immersed in the electrolyte,
which a solution where Ossila Hellmanex III, a cleaning substance with similar properties as
sodium hydroxide, was diluted with deionized water down to a concentration of 1 vol.%. Using
the Atten AFT20B Function Wave Generator to produce a sinusoidal signal, and the Accel
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Instruments TS-200 as the power source, alternating current with an amplitude of 3 kV and a
frequency of 3 kHz were applied to both the tungsten anode and the carbon cathode. While the
carbon cathode remained immersed in the electrolyte, the tungsten anode was raised and lowered
about 1-2 mm into the electrolyte for around five to ten minutes to create a pointed tip.

(a)

(c)

(b)

(d)

Figure 11: Schematic of (a) (standard) flat-surface nozzle; (b) tapered-surface nozzle; (c) flat-surface
nozzle with tungsten needle; and (d) tapered-surface nozzle with tungsten needle.

Throughout the study, nozzles of various inner diameters were considered, with the main
focus of using nozzles of smaller diameter in order to achieve droplets, and in turn, particles, of
smaller size, as prescribed in earlier sections.
Nozzle Materials
Beyond the shape and size of the nozzle, material properties were also considered in the
process of determining optimal conditions for producing the desired particles. As a reference point,
stainless steel was primarily used. From there, the issue of the solution wetting arose, in which the
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cone jet was disrupted due to the fluid clinging to the nozzle itself before being broken up into
droplets. Eventually, this led to the drug solidifying onto the nozzle, thereby introducing a clog
that further disrupted the formation of the stable jet necessary to make particles of consistent shape
and size.
To remedy such a problem, two avenues were considered: changing the material of the
nozzle, as well as introducing a hydrophobic coating. With regards to materials selection, the use
of fused silica nozzles were explored. More specifically, PicoTip Emitter SilicaTip tapered nozzles
sized at an inner diameter of 30 µm were used for all experiments regarding the use of fused silica
needles.
As for coatings, polydimethylsiloxane (PDMS) was primarily applied at the tips of both
stainless steel and fused silica nozzles. (30) The PDMS was obtained from Wacker Chemie AG in
the form of SILRES H62-C silicone resin. After the application of the coating, the needles were
then heated for one hour at 230 °C using the TRO480BS 4-Slice Toaster Oven from Black &
Decker.
Summary
Ultimately, the table below shows the specifications of all of the possible configurations of
nozzle material, inner diameter, coatings, geometry, and needle additives that are used throughout
the study. While not all combinations were utilized for deposition, some key differences in nozzle
configurations were explored in the study, including the presence of a concentric needle.
Throughout the remainder of the paper, the type of nozzle configuration used shall be referred to
by their numbers prescribed in the first column of Table 5.
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80 μm

Inner
Nozzle
Needle # Diameter

PDMS
Tungsten

Material

Geometry
(ID, µm)

Notes
Coating

Needle

1

160

Flat

No

Stainless Steel

No

2

160

Flat

No

Stainless Steel

Yes

3

160

Flat

Yes

Stainless Steel

No

4

160

Flat

Yes

Stainless Steel

Yes

5

160

Tapered

Yes

Stainless Steel

No

6

160

Tapered

Yes

Stainless Steel

Yes

7

100

Flat

No

Stainless Steel

Yes

8

100

Flat

Yes

Stainless Steel

Yes

9

100

Tapered

No

Stainless Steel

Yes

10

100

Tapered

Yes

Stainless Steel

Yes

11

30

Tapered

No

Fused Silica

No

30 µm ID silica

12

30

Tapered

No

Fused Silica

Yes

nozzle

30 g nozzle

100 µm
stainless steel
nozzle

Table 5: Nozzle configurations used throughout the study.

4.3.

Solution Properties
Preparation of Stock Docetaxel Solutions
With regards to preparation of the solvent, an Accumax JE-507124 measuring pipette was

used to mix dimethyl sulfoxide into ethanol in a 25 mL vial with a nine-to-one volume ratio, so as
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to produce a solvent that is 10 vol. % DMSO and 90 vol. %. Using a Veritas M124A weighing
scale, vitamin E TPGS, a solid, was measured onto an empty vial. Serial dilution was then utilized
to measure enough of the liquid mixture in such a way that a solvent containing 0.05 wt. % vitamin
E TPGS is prepared.
From there, the weighing scale was used to measure enough docetaxel in a separate vial to
produce a solution that entails 2 wt. % of the drug and the remainder of the weight consisting of
the solvent.
Overall, the solution in which 2 wt. % docetaxel dissolved in a solvent consisting of 0.05
wt. % vitamin E TPGS mixed into 10 vol. % DMSO and 90 vol. % ethanol was considered the
base solution from which experiments will be run. Additives are introduced later on to serve as
variables that may affect particle morphology.
Fluid Conductivity
Previous literature has shown that the addition of trace amounts of salt to a solution has the
capability to boost its conductivity in reference to electrospray atomization. (24) Such an increase
can be quantified by means of measuring the output current during sample collection. In this study,
the concept of solution conductivity was explored upon to determine its effects on the shape and
size of deposited powders.
For all solutions containing the sodium salt, the additives were incorporated into the stock
docetaxel solution by first dissolving 1 wt. % sodium salt in deionized water. From there, various
amounts of the saline solution were transferred onto the stock docetaxel solution by means of
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pipette. However, before electrospray deposition, the electrical conductivity of the solution was
determined by using an ohmmeter capable of measuring in the order of megaohms, with two
outgoing alligator clips attached to two 30-gauge needles providing the surface S described in
Figure 12 below. (31)

Figure 12: Schematic of the method used to determine electrolytic conductivity of solutions.

In the preliminary stages of the study, three different concentrations of salt were
considered: no salt, 0.03 wt. % (300 ppm), and 0.05 wt. %. (500 ppm). However, the 0.05 wt. %
level of salt additive was phased out due to producing results that are extremely similar to that of
the 0.03 wt. % level of salt additive. It has been determined that the latter two concentrations of
salt were relatively similar in terms of order of magnitude, so the study was committed to using
either no salt or 0.03 wt. % salt.
Surfactants
After experiments were performed in solutions regarding the presence or lack of sodium
salt, additional experiments were performed pertaining to whether or not the TPGS additive should
remain included or not. Thus, four different solutions were used with regards to experimenting
with omitting the surfactant are as follows:
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 Solution 1: No sodium salt or vitamin E TPGS added
 Solution 2: No sodium salt, but 0.05 wt. % vitamin E TPGS added
 Solution 3: 0.03 wt. % sodium salt added, but no vitamin E TPGS
 Solution 4: Both 0.03 wt. % sodium salt and 0.05 wt. % vitamin E TPGS added
Out of the four, upon determination of which solution works best, a second series of
experiments were performed with regards to nozzle and needle properties.

4.4.

Deposition Conditions
Electrospray Conditions
Through both literature and preliminary experimentation, it has been discovered that the

best way to produce finer particles of the drug was to minimize the size of the droplets being
produced by electrospray. In order to do so, several avenues were considered: increasing the
applied voltage, increasing the working distance, and decreasing the flow rate. However, each
option has its maximum (or minimum for the flow rate) allowable value, as exceeding such
thresholds can reduce or even eliminate the jet stability needed to consistently produce
monodisperse droplets.
Ultimately, electrospray parameters were fixed at flow rates of either 1.0 µL/min or 0.5
µL/min were adapted, with an applied voltage ranging from 2.5 kV – 3.0 kV. The working distance
was established to between 3 cm and 4 cm, with significant changes were observed upon the slight
variation in working distance.
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Two different avenues for particle collection were utilized thoroughly: small (i.e.
approximately 2 cm in diameter) disks of aluminum foil in earlier studies, and roughly 1 cm × 1
cm squares of silicon wafers in later studies. The substrate at which the particles were collected
exhibited no signs of reacting with the drug itself, and had therefore no effect on the particle
morphology itself.
Thermal History
Experiments with the variation of thermal history were performed by placing silicon wafer
collection chips on top of a Cole-Parmer StableTemp heat plate. Preliminary experiments were
performed to determine if any increase in temperature had any effect on particle morphology. In
this earlier study, a docetaxel solution (same concentrations as previous solutions) containing 0.05
wt. % salt and 0.05 wt. % vitamin E TPGS was electrospray deposited using Nozzle 11 at a flow
rate of 1.0 µL/min and a working distance of 4 cm. Two different temperature levels were then
considered: room temperature (20 °C) and 70 °C
In later stages of the study, the concept of thermal history was re-visited upon the discovery
of better electrospray conditions. In the later stages, experiments were largely performed with
Solution 3 being the main solution under study. Two different temperature stages were considered:
room temperature (20 °C), and 45 °C. To eliminate additional variables, Needle 8 in the catalog
prescribed above was primarily used, along with a flow rate of 0.5 µL/min and similar working
distances and applied voltage.
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4.5.

Characterization of Particle Morphology
After particle collection, the silicon wafers were then characterized by means of scanning

electron microscopy (SEM). In order to achieve this, the wafers were first sputter-coated using the
Emitech K550X Sputter Coater at a current of 20 nA for approximately two minutes. From there,
the particles themselves were viewed using the Zeiss ULTRA-55 FEG SEM, which was provided
by UCF’s Materials Characterization Facility.
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Chapter Five: Results and Discussion
5.1.

Solution Properties
Electrolytic Conductivity
To compare the effectiveness of salt in increasing the conductivity of the particles, which

is a significant component in reducing the overall size of the electrosprayed particles, Solutions 2
and 4 as described in Section 4.3.3 were deposited and compared to each other. In this case, the
solutions were prepared using paclitaxel as opposed to docetaxel, though the differences in
behavior and particle morphology were considered negligible, as the two drugs are almost identical
in molecular structure with slight differences in substituents. To eliminate other variables, the two
solutions were electrosprayed in separate trials using Nozzle 12 as described in Section 4.2.3 at a
flow rate of 0.5 μL/min at room temperature, with a working distance of 3 cm and an applied
voltage of 2.5 – 3 kV.
Before SEM characterization was performed on the deposited particles, a conductivity test
was performed as described in Section 4.3.2, with the results listed in Table 6. The two fluids were
compared to ethanol, which served as the control group for the test.
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Fluid

Resistance

Electrospray Current

Ethanol

9.5 MΩ

–

Solution with no NaCl

1.74 MΩ

33.5 nA

Solution with 0.03 wt.%

0.03 MΩ

124 nA

NaCl
Table 6: Measured conductivities of electrosprayed solutions, compared in terms of vitamin E TPGS
presence.

As expected, the introduction of table salt to the solution, even at miniscule amounts, was
substantial in decreasing the measured resistance between the two measurement electrodes by
about two orders of magnitude. With regards to the current output measured in the electrospray
deposition process, at constant voltage, the resistance is expected to be inversely proportional to
the deposition current, and this is reflected increase in the current by a factor of about 3.70. The
significant spike in the current is reflected in previous literature, in which the strong electrolytes
that are sodium and chloride ions provided by the table salt are largely responsible for increasing
the flow of charges in the circuit path established by the electrospray system. (24)
On the context of particle morphology, the increase in current has translated to an extensive
reduction in the particle size of the paclitaxel particles. The SEM samples shown in Figure 13
reflects such an observation in a visual manner, and is also quantified by the 95% confidence
intervals presented in Table 7.
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(a)

(b)

Figure 13: Morphology of docetaxel particles without the addition of vitamin E TPGS (a) no salt added,
(b) 0.03 wt.% salt added.

Solution Type

Sample Size

95% CI of Particle Size, nm

No NaCl

N=6

452.48 ± 36.53

0.03 wt.% NaCl

N=6

134.92 ± 28.85

Table 7: 95% confidence intervals of the sizes of electrosprayed docetaxel particles, with and without
sodium salt.

As demonstrated through SEM characterization and a brief particle size analysis, the
addition of a trace amount of table salt to the deposited solution had an indirect influence on
substantially reducing the particle size down by a factor of around 3.25. However, besides the
reduction in size, the introduction of additional electrolytes has also led to an aggregation of
particles. In spite of much larger particles, the absence of the electrolytes from the table salt has
translated to a much larger dispersion across the substrate. On the other hand, as demonstrated in
Figure 13b, the introduction of salt has not only drastically reduced the particle size, but has also
led to a more inconsistent particle distribution, wherein particles were more likely to form clusters
with each other. Moreover, the manner at which these particles adhere to each other has often led
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to the creation of a large network of aggregates, which provides a web-like appearance for the
particle morphology on the micrometer scale.
One possible explanation for such a phenomenon is that, while the salt itself does not react
with the cancer drug and make significant changes to the overall molecular structure, the ions
themselves do embed with the drug molecules as the liquid solvent dries up, thereby increasing
the intermolecular forces that exist from one particle to another. Additionally the more elongated
shapes of each clusters could largely be due to trajectories of each particle as they diffuse from
monodisperse droplets, as they all start out from the same point (the opening of the nozzle or the
tip of the tungsten needle) and diverge from there. The presence of ions from the salt then exerts
much greater influence when it comes to how the particles are positioned on the substrate.
Surfactant Presence
In a similar manner as to determining the effects of the presence of vitamin E TPGS
towards particle morphology, the effects of adding or omitting the vitamin E surfactant was
determined, for the first experiment, by first measuring the electrolytic conductivity of the solution
using methods described in Section 4.3.2, which produced results tabulated in Table 8. For this
experiment, Solution 1 and Solution 2, as described in Section 4.3.3, were compared to each other.
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Fluid

Resistance

Electrospray Current

Solution with no vitamin E

1.74 MΩ

33.5 nA

2.00 MΩ

38.0 nA

TPGS
Solution with 0.05 wt.%
vitamin E TPGS
Table 8: Measured conductivities of electrosprayed solutions, compared in terms of vitamin E TPGS
presence.

As indicated by Figure 5-4, there was no significant difference in electrolytic conductivity
between the two solutions, which is expected in that the surfactant, as a bulky organic molecule,
is not expected to ionize in the same way that salt does.
From there, the two solutions were electrosprayed using Nozzle 12, as described in Section
4.2.3, with a flow rate of 0.5 μL/min at room temperature, a working distance of 3 cm, and an
applied voltage of 2.5 – 3 kV.
The SEM characterization in Figure 14 shows that, as for the morphology itself, there was
no change overall shape of the docetaxel particles. In both the control and experimental groups,
with no ions from the salt to expedite the droplet formation process via an increased current, the
particles took on much larger sizes (i.e. a diameter of around 400-450 nm).
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(a)

(b)

Figure 14: Morphology of docetaxel particles (a) no vitamin E TPGS added, (b) with 0.05 wt.% vitamin E
TPGS. Neither solution has any added salt.

However, upon conducting a brief statistical analysis on the size of the individual particles,
a slight but noticeable difference in size between the two sets of particles. The 95% confidence
intervals presented in Table 9 shows that, on average, the solution with the surfactant present was
approximately 46 nm larger than its surfactant-free counterpart.
Sample

95% CI of Particle Size, nm

Two-sample 95% CI,

Solution Type
Size

nm

No vitamin E TPGS

N=6

406.25 ± 62.03

0.05 wt.% vitamin E

N=6

452.28 ± 36.53

46.23 ± 64.27

TPGS added
Table 9: 95% confidence intervals of the sizes of electrosprayed docetaxel particles, with and without
vitamin E TPGS.

This 50 nm difference may be attributed to the fact that the surfactant has naturally formed
micelles around each drug particle, thereby naturally increasing the overall diameter of the
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particles by a slight amount. Such results reflect how the vitamin E TPGS surfactant behaves
around docetaxel and paclitaxel, as described by previous literature. (8)
In order to verify such a phenomenon, a second experiment was carried out, this time with
the addition of 0.03 wt. % table salt (i.e. Solutions 3 and 4 as described in Section 4.3.3), similar
to the procedures described to perform the previous experiment at the beginning of this section. A
similar nozzle, flow rate, operating temperature, and working distance as the first experiment was
used to remove other unnecessary variables. With the addition of salt, particles from both sets of
deposited docetaxel were expected to be much smaller and, in terms of morphology, cluster
together and create a web-like appearance, which is reflected in Figure 15.

(a)

(b)

Figure 15: Morphology of docetaxel particles (a) no vitamin E TPGS added, (b) with 0.05 wt.% vitamin E
TPGS. Both solutions contained 0.03% salt by weight.
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Sample

95% CI of Particle Size, nm

Two-sample 95% CI,

Solution Type
Size

nm

No vitamin E TPGS

N=6

134.92 ± 28.85

0.05 wt.% vitamin E

N=6

216.62 ± 28.03

40.85 ± 30.16

TPGS added
Table 10: 95% confidence intervals of the sizes of electrosprayed docetaxel particles, with and without
vitamin E TPGS, for the solutions containing 0.03 wt.% salt.

As shown above in Table 10, the 95% confidence interval for the difference in particle
sizes between the two sets of electrosprayed docetaxel particles, which was calculated to be around
41 nm, was roughly similar to the difference obtained from the first experiment, in spite of the
diminished margin of error. This roughly constant difference across two largely different particle
sizes (between adding and omitting the saline solution) demonstrates that the micelles behave in a
consistent manner regardless of the presence of the saline solution.

5.2.

Nozzle Properties
In this part of the study, the exploration of the concentric tungsten needle was performed

with the main goal of being able to facilitate the formation of a stable jet, which can be indirectly
measured by calculating the variation of the sizes of the particles produced. A smaller variation in
particle size implies a better control of the stability of the cone jet. Here, such a claim was
compared to the hypothesis that the addition of a concentric needle to a larger nozzle can achieve
results that are similar to that of a standalone nozzle that is already small.
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Here, Nozzle 10 was compared to Nozzle 12 (as listed in Section 4.2.3) through separate
electrospray depositions of Solution 3 (as described in Section 4.3.3) using the two nozzles. In
both trials, the solution was deposited with a flow rate of 0.5 μL/min at room temperature.
A key characteristic in determining nozzle configuration is the clearances provided in
which the solutions can pass through. For Nozzle 10, with an inner diameter of 100 μm and a
concentric needle 80 μm in diameter, an opening in the form of an annulus that is 900π μm2 in area
exists for the solution to pass through. On the other hand, Nozzle 12 yields an inner diameter of
30 μm, which translates into a 225π μm2 opening. The effects of having the two different openings
on the morphology of the docetaxel particles were recorded through SEM characterization
provided in Figure 16 and a brief statistical analysis provided in Table 11.

(a)

(b)

Figure 16: Morphology of docetaxel particles (a) electrosprayed using a PDMS-coated silica nozzle,
having ID = 30 μm, (b) electrosprayed using a PDMS-coated stainless steel nozzle with concentric
tungsten needle, which yielded a clearance of t = 20 μm.
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Nozzle Configuration

Sample Size

95% CI of Particle Size, nm

Nozzle 10 (100 μm stainless

N=9

110.50 ± 16.25

N=6

134.92 ± 28.85

steel nozzle with 80 μm
tungsten needle, SAopen = 900π
μm2)
Nozzle 12 (30 μm silica
nozzle, SAopen = 225π μm2)
Table 11: 95% confidence intervals for particle sizes in the experiment involving the concentric tungsten
needle.

Thus, in spite of Nozzle 12 (silica nozzle) having one-fourth the opening surface area for
the fluid to pass through, it produced particles that is slightly larger than Nozzle 10 simply because
of the fact that the needle present in Nozzle 12 exerts a lot of influence with the stabilizing of the
jet. The needle, being made of tungsten, a highly conductive metal, attracts the solution molecules
that flow through the much larger nozzle. These molecules, which have been charged beforehand
to 2.5 – 3 kV from a voltage source, converge onto the tip of the tungsten nozzle, which provided
a highly strong electric field due to the sharp point at the tip (i.e. an extremely small radius). In
turn, this small convergence area led to smaller monodisperse droplets and, in turn, smaller
docetaxel particles produced.
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5.3.

Thermal History
Particle Size Analysis
With regards to determining the effects of thermal history, two different experiments were

carried out to ensure consistency. The first experiment, as noted earlier in Section 4.4.2, were
carried out using a docetaxel solution entailing 0.05 wt. % salt and 0.05 wt. % vitamin E TPGS,
with Nozzle 11 from Section 4.2.3 as the atomizer, and a flow rate of 1.0 μL/min. In this trial, two
different temperature stages were used: room temperature (roughly 20 °C) and 70 °C, which is
close to the boiling point of ethanol, the largest component in the electrosprayed solutions in terms
of the percent composition. Figure 17 contains the SEM samples that were taken at the conclusion
of the experiment.

(a)

(b)

Figure 17: Morphology of docetaxel particles (a) electrosprayed at room temperature, (b) electrosprayed
at a substrate heated to 70 °C

Table 12 lists the 95% confidence intervals of the particle sizes at the two different
temperature stages.
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Electrosprayed Temperature

Sample Size

95% CI of Particle Size, nm

Room Temperature (20 °C)

N=6

152.18 ± 49.68

Heated (70 °C)

N=9

283.71 ± 102.73

Table 12: 95% confidence intervals for particle sizes in the first experiment involving thermal history.

As for the second experiment, the solution chosen for study was Solution 3 from Section
4.3.3, with Nozzle 8 from Section 4.2.3, and a flow rate of 0.5 μL/min. Here, two different
temperature stages were also used: room temperature and 45 °C, which is chosen due to the fact
that it approximately marks the halfway point between room temperature and the boiling point of
ethanol. Figure 18 contains the SEM samples that were taken at the conclusion of the experiment.

(a)

(b)

Figure 18: Morphology of docetaxel particles (a) electrosprayed at room temperature, (b) electrosprayed
at a substrate heated to 45 °C

Similarly, 95% confidence intervals for the samples of the second experiment were
prepared in Table 13.
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Electrosprayed Temperature

Sample Size

95% CI of Particle Size, nm

Room Temperature (20 °C)

N=8

107.00 ± 20.24

Heated (45 °C)

N=8

108.21 ± 19.83

Table 13: 95% confidence intervals for particle sizes in the second experiment involving thermal history.

In the first experiment, the variation amongst the particle sizes were largely due to the fact
that the experimental temperature of 70 °C is extremely close to the evaporation temperature of
the ethanol. Here, the varied thermal history has a more competitive role as compared to the
important electrospray properties, namely the flow rate and the size of the nozzle. At a flow rate
of 1.0 μL/min and a nozzle cross-sectional diameter of 30 μm, there has been a tendency to
particles that are much larger in terms of diameter (i.e. 150 – 300 nm). With such sizes, as well as
a temperature level closer to the boiling point, the temperature of the substrate has a stronger
influence on the appearance of the particles. As evidenced by the 95% confidence intervals, the
docetaxel powders deposited at the higher temperature level exhibited a margin of error that is
twice in size compared to that of the powders deposited at room temperature.
As for the second experiment, it is expected for the variation and differences in mean of
the particle sizes between the control group and the experimental group to not be as pronounced
as compared to the first experiment. This can be attributed to the fact that, in spite of a larger
overall inner diameter for the nozzle (100 μm as opposed to 30 μm), the addition of the tungsten
needle that is 80 μm in diameter has resulted in an annulus with a thickness, and therefore a net
clearance, of 10 μm for the solution to pass through. Combined with the reduced flow rate and the,
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the sizes at which the droplets were formed were expected to be smaller compared to that of the
first experiment. However, for the second experiment, the extent at which the effects of thermal
history has affected the size of the dry particles was not as prevalent as compared to the first
experiment. In this case, the electrospray parameters and nozzle selection at which the docetaxel
was deposited had more dominance over the effects of the particle size than the temperature of the
substrate. As the two confidence intervals indicate, the difference between the mean and spread of
the sizes of the two sets of particles are almost negligible for the second experiment.
Particle Geometry Analysis

(a)

(b)

(c)

Figure 19: Docetaxel particle electrosprayed at (a) room temperature, (b) 45 °C, and (c) 70 °C, with all
other parameters kept constant.

The effects of an increase in substrate temperature, however, was more noticeable in terms
of the shape of the dry docetaxel particles. As illustrated above in Figure 19, most of the dry
docetaxel particles deposited at room temperature seem to convey the morphology of voided
hemispheres. Additionally, the lowered temperature enabled the particles to aggregate together in
clumps, thereby providing inconsistent particle distribution across the substrate.
Moving up to a substrate temperature of 45 °C, a rounder shape was more easily observed
amongst particles. Most of the particles started to take on either the shape of a pill or a sphere, with
flattened or holed disks becoming not as prevalent. At this temperature stage, however,
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aggregation was still evident, though the aggregates themselves were more consistent in that the
clumps were of the same size, and were more evenly spread as compared to the particles deposited
at room temperature.
Lastly, at 70 °C temperature near the boiling point of the dominant solvent (ethanol), the
spherical shape of the deposited particles became much more apparent. At this temperature level,
the aggregation of multiple particles in clumps, which were observed at room temperature and at
45 °C, was close to nonexistent. Instead, individual particles were more dispersed across the
substrate, and could easily be told apart from each other in SEM characterization.
Such observations regarding particle shape and dispersion tendencies reflect the literature
presented regarding particle morphology, wherein particles with a low Peclet number (Pe << 1)
tend to be almost always spherical, whereas particles with a higher Peclet number (Pe > 1) tend to
convey large voids and resemble incomplete spheres. The morphologies achieved through
experimentation at the different temperature stages reflect such assertions presented by previous
studies. However, further research may be carried out in the future to determine such a threshold.
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Chapter Six: Conclusions
In summation, it has been determined that electrospray deposition is a promising conduit
for the processing of bulk docetaxel and even paclitaxel into monodisperse nanoparticles. Through
the electrospray atomizer’s ability to produce droplets at a consistent size and rate, these droplets
can consistently diffuse into particles of consistent size and shape. And through manipulation of
different parameters, ranging from electrospray parameters and nozzle properties (both material
and geometric), to the solution properties (in terms of both composition and constituents present
or absent), the exact geometry of the particles produced can be easily manipulated to desired
characteristics.
Moreover, the binary solvent system proved to be a strong candidate mixture for the
docetaxel to be dissolved in. Oftentimes, in current pharmaceutical markets, docetaxel and
paclitaxel are often sold as powdered drugs that are dissolved in an alcoholic solution, usually
methanol. (5) However, in this study, a mixture of solvents, with primary focus on pairing ethanol
with DMSO, was utilized. With prolonged evaporation rates presented by the binary solvent
system, one can gain better command of the particle diffusion process in terms of altering the
Peclet number to one’s favor by altering other parameters instead, such as operating temperature.
However, one significant drawback that is prevalent in this study is the low yield of the
desired drug particles. This can largely be attributed to the smaller flow rate that is necessary to
produce particles at the desired nanoscale size. However, future studies could be performed to
easily circumvent this issue, wherein the multiplexing of electrospray atomizers could be explored
in greater detail. (32)
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